AtaiBeckley Inc. - Common Stock (ATAI)

The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions.

Demand for the healthcare leader's weight-loss drugs continues to rise.

Lilly's pipeline is on track to pick up a handful of interesting new programs.

Cathie Wood is loading up on shares of a biotech that could be one of the first entrants to the psychedelics market.

The company isn't resting on its laurels.

Lilly's purchase of AtaiBeckley is yet another strategic move in its bid to diversify its pipeline.

The psychedelic drugmaker is being acquired.

Today, July 16, 2026, the clinical-stage psychedelics developer jumped 33% after Lilly announced a cash deal plus milestone payments.

Gainers AtaiBeckley (NASDAQ:ATAI) stock rose 34.3% to $7.2 during Thursday's pre-market session. The market value of their outstanding shares is at $1.9 billion. Agape ATP (NASDAQ:ATPC) shares moved upwards by

Hershberg exercised vested options and liquidated them under a Rule 10b5-1 plan, halving direct equity while retaining 404,869 derivative securities.

President Trump wants to fast-track psychedelic research.

AtaiBeckley (NASDAQ:ATAI) shares are surging Monday as psychedelic biotechs rally on President Trump's executive order to fast-track reviews.

Trump is easing approval for psychedelic treatments for mental disorders.